Protalix Biotherapeutics, Inc.

286 articles about Protalix Biotherapeutics, Inc.

• 

  FDA Action Alert: Sarepta, Protalix, Otsuka/Lundbeck and More

  5/8/2023

  The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy.

• Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results

  5/4/2023

  Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

• Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023

  4/27/2023

  Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the first quarter ended March 31, 2023 and provide a business update on Thursday, May 4, 2023.

• Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

  3/21/2023

  Protalix BioTherapeutics, Inc. today announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treatment of severe gout.

• Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

  3/13/2023

  Protalix BioTherapeutics, Inc. announced today that it does not hold cash deposits or securities at either Silicon Valley Bank or Signature Bank, nor does it have any credit facility or other financial relationship with either institution.

• Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

  2/27/2023

  Protalix BioTherapeutics, Inc. today reported financial results for the fiscal year ended December 31, 2022 and provided a business update on recent corporate and regulatory developments.

• Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

  2/24/2023

  Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX–102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.

• Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023

  2/21/2023

  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.

• Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023

  2/21/2023

  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.

• Protalix BioTherapeutics Issues 2023 Letter to Stockholders

  1/3/2023

  Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.

• Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange

  12/21/2022

  Protalix BioTherapeutics, Inc. announced that the Company's management and Board of Directors have decided that it is in the best interest of the Company to voluntarily delist its common stock from the Tel Aviv Stock Exchange.

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

  12/5/2022

  Protalix BioTherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.

• Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102

  12/4/2022

  Protalix BioTherapeutics, Inc. announced that the Company will host a key opinion leader webinar on Fabry Disease and PRX-102 on Monday, December 5, 2022 at 8:30 a.m. Eastern Standard Time.

• Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results

  11/14/2022

  Protalix BioTherapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments.

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

  11/14/2022

  Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced the resubmission on November 9, 2022 of a Biologics License Application to the U.S. Food and Drug Administration for PRX–102 for the treatment of adult patients with Fabry disease.

• Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022

  11/7/2022

  Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.

• Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference

  9/12/2022

  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present in person on Wednesday, September 14, 2022 at 11:00 a.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 24th Annual Global Investment Conference.

• Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Protalix BioTherapeutics, Inc. announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference.

• Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results

  8/15/2022

  Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2022 and provided a business update on recent corporate and regulatory developments.

• Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022

  8/8/2022

  Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the second quarter 2022 and provide a business update on Monday, August 15, 2022.